The work involves design and fabrication of a new microfluidic platform to synthesize palladium (Pd) nanoparticles coated with trimethyl chitosan (TMC), for biomedical applications. TMC-coated palladium nanoparticles (TMC/Pd NPs) were prepared in continuous mode, using the microfluidic reactor. Droplet-generation approach was adopted since it provides a high degree of control over mixing and reagent loading. However, one major limitation was the cumbersome recovery of the synthesized nanoparticles, which required laborious “off-chip” procedures like droplet separation and nanoparticle re-suspension. These issues were overcome using the continuous flow microfluidic system integrated with separation system, to enable rapid synthesis and retrieval of TMC/PdNPs using a single platform. The synthesized nanoparticles were spherical, having an average diameter of 35–40 nm. These TMC/Pd NPs are yet unexplored for biomedical applications. Thus, their biocompatibility and cellular uptake was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, confocal microscopy and binding kinetics assay (Ligand Tracer® Green), which indicated the suitability of the formulation for biomedical applications.

这项工作涉及设计和制造新的微流控平台，以合成涂有三甲基壳聚糖（TMC）的钯（Pd）纳米颗粒，用于生物医学应用。使用微流体反应器，以连续模式制备了TMC涂层的钯纳米颗粒（TMC / Pd NPs）。采用了液滴产生方法，因为它可以高度控制混合和试剂的装载。然而，一个主要限制是合成纳米粒子的繁琐回收，这需要费力的“芯片外”程序，如液滴分离和纳米粒子重悬浮。使用与分离系统集成的连续流微流控系统可以克服这些问题，从而能够使用单个平台快速合成和检索TMC / PdNPs。合成的纳米颗粒是球形的 平均直径为35–40 nm。这些TMC / Pd NP尚未用于生物医学应用。因此，使用3-（4,5-二甲基噻唑-2-基）-2,5-二苯基溴化四溴甲烷（MTT）测定，共聚焦显微镜和结合动力学测定（LigandTracer®Green）评估了它们的生物相容性和细胞摄取。该制剂对生物医学应用的适用性。